Zacks: Analysts Expect SOPHiA GENETICS SA (NASDAQ:SOPH) Will Post Earnings of -$0.33 Per Share

Equities analysts expect that SOPHiA GENETICS SA (NASDAQ:SOPHGet Rating) will report earnings of ($0.33) per share for the current quarter, Zacks reports. Three analysts have made estimates for SOPHiA GENETICS’s earnings, with estimates ranging from ($0.36) to ($0.30). The firm is expected to report its next quarterly earnings report before the market opens on Monday, January 1st.

On average, analysts expect that SOPHiA GENETICS will report full year earnings of ($1.43) per share for the current fiscal year, with EPS estimates ranging from ($1.44) to ($1.41). For the next fiscal year, analysts forecast that the business will post earnings of ($1.33) per share, with EPS estimates ranging from ($1.46) to ($1.20). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that cover SOPHiA GENETICS.

SOPHiA GENETICS (NASDAQ:SOPHGet Rating) last announced its earnings results on Tuesday, March 15th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.01. The business had revenue of $10.94 million for the quarter, compared to analyst estimates of $11.27 million. SOPHiA GENETICS had a negative net margin of 182.14% and a negative return on equity of 39.82%.

SOPH has been the topic of a number of analyst reports. Morgan Stanley lowered their price objective on shares of SOPHiA GENETICS from $18.00 to $17.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 16th. Zacks Investment Research upgraded shares of SOPHiA GENETICS from a “sell” rating to a “hold” rating in a research report on Wednesday, March 16th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, SOPHiA GENETICS has an average rating of “Buy” and an average price target of $20.67.

Shares of SOPH opened at $7.00 on Friday. The company’s 50 day simple moving average is $9.64 and its 200-day simple moving average is $12.54. SOPHiA GENETICS has a 12-month low of $6.26 and a 12-month high of $19.80.

Institutional investors have recently added to or reduced their stakes in the business. Generation Investment Management LLP acquired a new position in shares of SOPHiA GENETICS during the 3rd quarter worth $121,099,000. Credit Suisse AG acquired a new position in shares of SOPHiA GENETICS during the 3rd quarter worth $32,998,000. Jennison Associates LLC raised its stake in shares of SOPHiA GENETICS by 123.4% during the 4th quarter. Jennison Associates LLC now owns 1,441,590 shares of the company’s stock worth $20,326,000 after buying an additional 796,173 shares during the last quarter. Principal Financial Group Inc. raised its stake in shares of SOPHiA GENETICS by 7.2% during the 4th quarter. Principal Financial Group Inc. now owns 881,395 shares of the company’s stock worth $12,428,000 after buying an additional 58,930 shares during the last quarter. Finally, Pura Vida Investments LLC acquired a new position in shares of SOPHiA GENETICS during the 3rd quarter worth $7,889,000. 29.08% of the stock is owned by institutional investors.

About SOPHiA GENETICS (Get Rating)

SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide.

See Also

Get a free copy of the Zacks research report on SOPHiA GENETICS (SOPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.